严禁买药赠药、积分换药，处方药网售迎强监管

Core Viewpoint - The article discusses the release of the "Compliance Guidelines for Online Retail of Prescription Drugs" by the National Medical Products Administration, which aims to enhance the regulation and safety of online prescription drug sales in China [4][5]. Group 1: Compliance Requirements - The Compliance Guidelines outline five key compliance requirements for companies: qualification compliance, prescription review, risk control, platform responsibility, and traceability management, providing clear guidance for legal operations [5]. - The guidelines emphasize the necessity of prescription review and prohibit promotional activities such as free gifts or point redemption for prescription drugs to ensure public safety [5][8]. Group 2: Market Growth and Regulation - The online pharmaceutical sales market is projected to reach 71.77 billion yuan in 2024, with an annual growth rate of 18.03%, and is expected to exceed 80 billion yuan by 2025 [7]. - The guidelines are designed to promote healthy industry development and create a fair competitive environment for legitimate operators, transitioning the market from rapid growth to regulated, high-quality growth [7][9]. Group 3: Platform Responsibilities - The guidelines specify compliance requirements for both self-built and third-party platforms, emphasizing the need for accurate and traceable transaction information [11]. - Third-party platforms are required to establish drug quality safety management institutions and conduct thorough audits of the qualifications of online retail enterprises [12]. Group 4: Risk Prevention and Future Directions - The guidelines reflect a shift in drug regulation from passive punishment to proactive prevention, aiming to lower compliance costs and enhance efficiency [9]. - Future efforts in prescription drug regulation may include elevating successful guidelines to mandatory standards and leveraging technologies like big data and blockchain for better monitoring and transparency [13].